ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging. Dr. Olav E. Krigolson Lecture 5: PARKINSONS DISEASE

Similar documents
Parkinson Disease. Lorraine Kalia, MD, PhD, FRCPC. Presented by: Ontario s Geriatric Steering Committee

Parkinson s Disease. Sirilak yimcharoen

Optimizing Clinical Communication in Parkinson s Disease:

COGNITIVE SCIENCE 107A. Motor Systems: Basal Ganglia. Jaime A. Pineda, Ph.D.

III./3.1. Movement disorders with akinetic rigid symptoms

VL VA BASAL GANGLIA. FUNCTIONAl COMPONENTS. Function Component Deficits Start/initiation Basal Ganglia Spontan movements

Basal ganglia Sujata Sofat, class of 2009

Overview. Overview. Parkinson s disease. Secondary Parkinsonism. Parkinsonism: Motor symptoms associated with impairment in basal ganglia circuits

Visualization and simulated animations of pathology and symptoms of Parkinson s disease

Evaluation of Parkinson s Patients and Primary Care Providers

Parkinson s Disease: initial diagnosis, initial treatment & non-motor features. J. Timothy Greenamyre, MD, PhD

PARKINSON S DISEASE. Nigrostriatal Dopaminergic Neurons 5/11/16 CARDINAL FEATURES OF PARKINSON S DISEASE. Parkinson s disease

Subthalamic Nucleus Deep Brain Stimulation (STN-DBS)

10th Medicine Review Course st July Prakash Kumar

Faculty. Joseph Friedman, MD

Parkinson s Disease Initial Clinical and Diagnostic Evaluation. J. Timothy Greenamyre, MD, PhD

Issues for Patient Discussion

Movement Disorders. Psychology 372 Physiological Psychology. Background. Myasthenia Gravis. Many Types

Scott J Sherman MD, PhD The University of Arizona PARKINSON DISEASE

Enhanced Primary Care Pathway: Parkinson s Disease

Parkinson s Disease WHERE HAVE WE BEEN, WHERE ARE WE HEADING? CHARLECE HUGHES D.O.

A. General features of the basal ganglia, one of our 3 major motor control centers:

U n i f i e d P a r k i n s o n s D i s e a s e R a t i n g S c a l e ( U P D R S )

A. General features of the basal ganglia, one of our 3 major motor control centers:

Understanding Parkinson s Disease Important information for you and your loved ones

Making Things Happen 2: Motor Disorders

Treatment of Parkinson s Disease: Present and Future

Parts of the motor circuits

Extrapyramidal Motor System. Basal Ganglia or Striatum. Basal Ganglia or Striatum 3/3/2010

Motor Fluctuations in Parkinson s Disease

WELCOME. Parkinson s 101 for the Newly Diagnosed. Today s Topic: Parkinson s Basics presented by Cari Friedman, LCSW

The symptoms of the Parkinson s disease may vary from person to person. The symptoms might include the following:

Joint Session with ACOFP and Mayo Clinic. Parkinson's Disease: 5 Pearls. Jay Van Gerpen, MD

First described by James Parkinson in his classic 1817 monograph, "An Essay on the Shaking Palsy"

Parkinson s disease Therapeutic strategies. Surat Tanprawate, MD Division of Neurology University of Chiang Mai

The PD You Don t See: Cognitive and Non-motor Symptoms

Functional Distinctions

Evaluation and Management of Parkinson s Disease in the Older Patient

Deep Brain Stimulation: Indications and Ethical Applications

The motor regulator. 1) Basal ganglia/nucleus

Differential Diagnosis of Hypokinetic Movement Disorders

Neurodegenerative Disease. April 12, Cunningham. Department of Neurosciences

CN V! touch! pain! Touch! P/T!

2/20/18. History of Parkinson s. What is happening in the brain? DOPAMINE! Epidemiology. Parkinson s Disease. It s much more than tremor

Date of Referral: Enhanced Primary Care Pathway: Parkinson s Disease

Movement Disorders: A Brief Overview

Clinical Features and Treatment of Parkinson s Disease

Chapter 8. Parkinsonism. M.G.Rajanandh, Dept. of Pharmacy Practice, SRM College of Pharmacy, SRM University.

Parkinson s Disease Update. Presented by Joanna O Leary, MD Movement disorder neurologist Providence St. Vincent s

Movement Disorders Will Garrett, M.D Assistant Professor of Neurology

PARKINSON S PRIMER. Dr. Kathryn Giles MD, MSc, FRCPC Cambridge, Ontario, Canada

Program Highlights. Michael Pourfar, MD Co-Director, Center for Neuromodulation New York University Langone Medical Center New York, New York

Parkinson s Disease. Prevalence. Mark S. Baron, M.D. Cardinal Features. Clinical Characteristics. Not Just a Movement Disorder

Parkinson s Disease Associated Sleep Disturbance Ehsan M. Hadi, MD, MPH. Dignity Health Neurological Institute

PARKINSON S DISEASE 馬 萬 里. Chinese character for longevity (shou) Giovanni Maciocia

The Shaking Palsy of 1817

Headway Victoria Epilepsy and Parkinson s Centre

Parkinson s Disease Update

Dr. Farah Nabil Abbas. MBChB, MSc, PhD

M. Carranza M. R. Snyder J. Davenport Shaw T. A. Zesiewicz. Parkinson s Disease. A Guide to Medical Treatment

MAXIMIZING FUNCTION IN PARKINSON S DISEASE

8/28/2017. Behind the Scenes of Parkinson s Disease

The PD You Don t See: Cognitive and Non-motor Symptoms

DRUG TREATMENT OF PARKINSON S DISEASE. Mr. D.Raju, M.pharm, Lecturer

Disorders of Movement M A R T I N H A R L E Y N E U R O L O G Y

Treatment of Parkinson s Disease and of Spasticity. Satpal Singh Pharmacology and Toxicology 3223 JSMBS

Drug Therapy of Parkinsonism. Assistant Prof. Dr. Najlaa Saadi PhD Pharmacology Faculty of Pharmacy University of Philadelphia

2-The age at onset of PD is variable, usually between 50 and 80 years, with a mean onset of 55 years (1).

Making Every Little Bit Count: Parkinson s Disease. SHP Neurobiology of Development and Disease

Damage on one side.. (Notes) Just remember: Unilateral damage to basal ganglia causes contralateral symptoms.

10/13/2017. Disclosures. Deep Brain Stimulation in the Treatment of Movement Disorders. Deep Brain Stimulation: Objectives.

Hyperkinetic movement disorders are. Hyperkinetic Movement Disorders. Cases in Movement Disorders. James case. About Tom

UNIVERSITY OF JORDAN FACULTY OF MEDICINE DEPARTMENT OF PHYSIOLOGY & BIOCHEMISTRY NEUROPHYSIOLOGY (MEDICAL) Spring, 2014

Parkinson s Disease Current Treatment Options

Prior Authorization with Quantity Limit Program Summary

Movement Disorders. Eric Kraus, MD! Neurology!

Lecture XIII. Brain Diseases I - Parkinsonism! Brain Diseases I!

Parkinsonism or Parkinson s Disease I. Symptoms: Main disorder of movement. Named after, an English physician who described the then known, in 1817.

Parkinson's Disease KP Update

Alison Charleston 1 st September 2016

Pathogenesis of Degenerative Diseases and Dementias. D r. Ali Eltayb ( U. of Omdurman. I ). M. Path (U. of Alexandria)

PARKINSON S MEDICATION

Part I Parkinson Disease Diagnosis and Treatment

Basal Ganglia George R. Leichnetz, Ph.D.

Basal Ganglia. Steven McLoon Department of Neuroscience University of Minnesota

Best Medical Treatments for Parkinson s disease

DISORDERS OF THE MOTOR SYSTEM. Jeanette J. Norden, Ph.D. Professor Emerita Vanderbilt University School of Medicine

Strick Lecture 4 March 29, 2006 Page 1

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Assistant Professor of Neurology

RAMBAM. Revolutionary New Treatment for Parkinson s Disease Tremors. Health Care Campus. Information Guide & Treatment Options

DEMENTIA and BPSD in PARKINSON'S DISEASE. DR. T. JOHNSON. NOVEMBER 2017.

Moving fast or moving slow: an overview of Movement Disorders

History Parkinson`s disease. Parkinson's disease was first formally described in 1817 by a London physician named James Parkinson

Pharmacologic Treatment of Parkinson s Disease. Nicholas J. Silvestri, M.D. Associate Professor of Neurology

symptoms of Parkinson s disease EXCEPT.

parts of the gastrointenstinal tract. At the end of April 2008, it was temporarily withdrawn from the US Market because of problems related to

Palladotomy and Pallidal Deep Brain Stimulation

Non-Motor Symptoms of Parkinson s Disease

Connections of basal ganglia

Anatomy of the basal ganglia. Dana Cohen Gonda Brain Research Center, room 410

Transcription:

ASHI691: Why We Fall Apart: The Neuroscience and Neurophysiology of Aging Dr. Olav E. Krigolson krigolson@uvic.ca Lecture 5: PARKINSONS DISEASE

The Basal Ganglia

Primary motor cortex Execution of movement Cortical Motor System

Somatotopy in M1

Cortical Motor System Pre-motor cortex Movement planning/sequencing

Cortical Motor System Posterior parietal cortex (PPC) Sensory guidance of movement

Subcortical Motor System: Basal Ganglia

Basal Ganglia Circuit M1, PM SMA Cortex Indirect pathway GPe Striatum SNc Direct pathway Thalamus Gpi/SNr output is inhibitory Gpi/SNr input from the striatum is inhibitory, whereas input from the STN is excitatory STN excitatory inhibitory GPi/SNr

Parkinson s Disease M1, PM SMA Indirect pathway GPe Cortex Striatum SNc Direct pathway Thalamus Decreased output of SNc dopaminergic projections Decrease inhibition in direct pathway Increase excitation in indirect pathway Net effect: more inhibition of thalamus and therefore less excitatory input to motor cortex STN excitatory inhibitory GPi/SNr

Subcortical Motor System: Basal Ganglia So what is the basal ganglia circuit doing? M1, PM SMA Cortex Brake Hypothesis B.G. essentially acts like a brake to prevent unwanted movement Indirect pathway GPe STN Striatum SNc Direct pathway Thalamus excitatory inhibitory GPi/SNr

Subcortical Motor System: Basal Ganglia Behavioral effects when damaged can include Resting tremor Akinesia (paucity of mov t) Muscular rigidity Unstable posture Bradykinesia (slowness of voluntary mov t) Tic-like involuntary movements Hemiballism (sudden involuntary large scale mov t) Possibly obsessive compulsive disorder, Tourette s, stuttering Assorted cognitive deficits (e.g., aphasia) Parkinson s disease Huntington s disease

What is Parkinson s Disease?

Defining IPD Named after James Parkinson who published 'An Essay on the Shaking Palsy' in 1817, which established Parkinson s as a recognised medical condition. He studied at the London Hospital Medical College, qualifying as a surgeon in 1784 when he was 29.

The term "parkinsonism" refers to any condition that involves a combination of the types of changes in movement seen in Parkinson's disease, which happens to be the most common condition causing this group of symptoms.

Parkinson Disease (PD) Usually idiopathic Substantia nigra degeneration causes dopamine deficiency in striatum à motor symptoms Dopaminergic therapy relieves motor symptoms

Male or Female Ages 50 80 (can be earlier than 20) 55,000 in Canada (0.2% of population) Reduces life expectancy due to increased incidence of infection associated with chronic immobility

caused by progressive deterioration of dopamine producing nerve cells in the basal ganglia insufficient dopamine disturbs the balance between dopamine and other transmitters, such as acetylcholine. without dopamine, the nerve cells cannot properly transmit messages, and this results in the loss of muscle function. the exact reason that the cells of the brain deteriorate is unknown.

1. Dopamine producing neurons die 2. More Lewy bodies abnormal proteins that inhibit regular brain function

Pathology Depletion of pigmented dopaminergic neurons in SN Reduced dopaminergic output from SN Inclusion bodies (Lewy bodies) develop in nigral cells Degeneration in other basal ganglia nuclei Neurons in subthalamic nucleus become more active than usual in inhibiting activation of the cortex Bradykinesia

HO NH 2 HO Dopamine Dopamine concentrated in very specific groups of neurons collectively called the basal ganglia

Nigrostriatal system: motor control Mesolimbic: regulating emotional behavior Mesocortical: executive control, reinforcement learning

Defining IPD Multiple systems atrophy IPD Progressive supranuclear palsy Parkinsonism Drug-induced parkinsonism Lewy body dementia Vascular parkinsonism

Differential diagnosis of parkinsonism Parkinson disease (idiopathic or genetic) Parkinson-plus degenerations (dementia with Lewy bodies, progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy) Drug-induced parkinsonism (anti-dopaminergics) Rare but treatable in young people: Wilson disease and Dopa-responsive dystonia Other: vascular parkinsonism, brain trauma, CNS infection

Parkinson s Disease not just a motor problem: Depression Dementia Hallucinations Overall mental deterioration

Parkinson disease: Common early complaints Resting tremor Writing smaller; harder to do buttons Slowness, weakness, limb not working well Stiff or achy limb Stoop, shuffle-walk, dragging leg(s) Trouble getting out of chairs or turning in bed Low or soft voice Non-motor: anosmia, dream enactment, constipation, anxiety, depression, passiveness

Symptoms

Clinical features Bradykinesia Postural instability IPD Rigidity Resting Tremor

Clinical features Pill-rolling at rest Diminished: -On action Resting Tremor Arms/legs/ feet /jaw/tongue Present: -At rest -When distracted

Tremor An involuntary movement which may affect the head, limbs, or entire body. Most apparent when limb is related and supported Increased with stress Ceased during sleep Decreased with intentional movements Pill rolling tremor if most prominent in fingers and hand Most bothersome, yet least disabling of all symptoms

Clinical features Cogwheel rigidity (upper limbs) Flexed posture Rigidity Increased tone when opposite arm moves actively Lead pipe rigidity (legs)

Rigidity Muscular stiffness and increased muscle tone Patients usually unaware of rigidity but troubled with slowness More apparent to doctor than patient Cogwheeling (affect when moving arms)

Clinical features Difficulty initiating movement Reduced spontaneous blinking Bradykinesia Poor rapid fine movements (fingers) Facial immobility (hypomimia)

Bradykinesia/Akinesia Akinesia: inability to move Bradykinesia: slowness of movement

Clinical features Loss of postural reflexes Postural instabilit y Difficulty making turns Retropulsio n

Postural Instability Impaired righting ability Toe-first walk develops Decreased arm swing when walking Posture stooped, knees flexed while walking Unsteadiness while turning Falls will occur

Gait: Clinical features i) Stooping ii) Slow to initiate walking iii) Shortened stride iv) Rapid small steps (shuffling) v) Tendency to run (festinating) vi) Reduced arm swing vii) Impaired balance on turning Falls common in later stages. Parkinson s gait

Clinical features Speech -Monotone àtremulous, slurring dysarthria. -Soft, rapid, indistinct. Cognitive -Cognitive impairment in 1/3 of patients (loss of executive functions including planning/decisionmaking/controlling emotions). -Depression.

Clinical features -Constipation/heartburn/dribbling/ dysphagia/weight loss. -Greasy skin. -Micrographia (small cramped writing).

Clinical features

Postural Instability Impaired righting ability Toe-first walk develops Decreased arm swing when walking Posture stooped, knees flexed while walking Unsteadiness while turning Falls will occur

Stage 1 Mild one sided tremor or rigidity Affected arm in semiflexed position with tremor Patient leans to affected side

Stage 2 Bilateral involvement Early postural changes Slow, shuffling gait Decreased stride length

Stage 3 Pronounced gait disturbances Moderate generalization disability Balanced is a major problem Server tremor, rigidity and/or brandykinesia

Stage 4 Significant disability Limited ambulation with assistance

Stage 5 Loss of ability to function independently Brandykinesia very severe Independent mobility impossible

Treatment

Treatment of Parkinson s Disease Since PD is related to a deficiency of dopamine, it would be appropriate to administer dopamine Problem: Dopamine cannot cross BBB

Levodopa used to increase dopamine levels can cross the blood-brain barrier (dopamine cannot) once in CNS metabolized to dopamine

PD: meds for motor symptoms L-dopa (with carbidopa) is most effective and usually best tolerated Dopamine agonists (ropinirole, pramipexole) Others have only modest benefits (MAO-B inhibitors, anticholinergics, amantadine)

Debate as to why it works! Alleviates motor symptoms Not a cure!

Early PD: When to start meds? Drugs are symptomatic, not neuroprotective or neurotoxic Level of patient function is best guide Response to dopaminergic therapy (especially l-dopa) is the best available test for PD ** Remember the value of exercise! **

Which treatment to start? L-dopa most effective for motor symptoms in general (bradykinesia, tremor, gait changes) Family physicians can start levodopa!! Dopamine agonists cause more non-motor side effects, and are best avoided in patients above 70

Treatment pearls in early PD Fear not L-dopa. Delaying L-dopa is of no benefit long-term. Treat more for symptoms and function, and less for how the patient looks. Generics are fine. Allow adequate dose and time to work before concluding failure or not PD. Resting tremor may be medication refractory in some patients; don t conclude not PD.

Levodopa Most effective overall for motor symptoms A fine option for initial therapy of PD By mid to late disease it is almost always needed Non-motor side effects include nausea, orthostasis, sleepiness, hallucinations; but not as much as other PD drugs Motor side effect: dyskinesias

Dopamine agonists (ropinirole, pramipexole, rotigotine) Can be monotherapy in early disease; need l-dopa in mid to late disease Can add to l-dopa to reduce OFF time Frequent side effects! Nausea, sleep attacks, hypotension, compulsive behaviors, LE edema L More prone than l-dopa to causing hallucinations and confusion. Caution in older or demented patients! L

Mid to late PD: a tricky business More motor complications including dyskinesias and ON-OFF fluctuations More drug-resistant motor symptoms (e.g. impaired balance with falls) More nonmotor symptoms (especially dementia and hallucinations) More medications, so more side effects Managing these complexities requires experience.

Motor complications as PD progresses Fluctuations. Medication wears off before next dose. OFF periods worse as disease progresses. Dyskinesias (usually at the peak of ON). Need larger and/or more frequent med doses, or combinations of drugs. Deep brain stimulation an option for some patients with medically refractory motor complications.

Depression and anxiety It s not just because of the stress of the diagnosis Motor symptoms and wearing off can interact with mood and anxiety levels Can misinterpret poker face as depression. Ask the patient! SSRI s can work; avoid benzodiazepines 74

Depression and anxiety: other considerations Consider support services / psychotherapy for patients and caregivers Geriatric psychiatrists usually have better expertise in this population 75

REM sleep behavior disorder Typically in men, often years before motor symptoms Complex movements or fighting Usually early in the morning, varying frequency Patient or bed partner injury 76

Insomnia Can be primary or secondary Address sleep hygiene Review med list Treat nighttime motor symptoms Think about OSA Treat psychiatric comorbidities Sedative/ hypnotics: melatonin, trazodone, mirtazapine, clonazepam (if RBD) 77

Hypersomnia PD increases sleep need for many patients Poor sleep at night (many causes) Think about OSA Review med list (make special note of dopamine agonists, anticholinergics, benzos, other sedatives) 78

Fatigue Tired, Wiped out, No energy Is it: Sleepiness? Wearing off? Motor? Mood? Isolated fatigue can be disabling No established treatment, though antidepressants and stimulants have been tried Encourage light exercise, hobbies, etc We badly need better treatments for this 79

Hallucinations & Dementia in PD Complicate many longstanding PD cases Hallucinations are usually visual Main contributors are disease progression (brain pathologic changes), age, and meds Older patients much more at risk Marker for increased morbidity, mortality, and institutionalization